PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results
Nachrichtenquelle: globenewswire | 13.05.2021, 13:00 | 43 | 0 FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today.
Recent Business Highlights:
National Cancer Institute to present interim efficacy and safety data of PDS0101 Phase 2 clinical trial in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting on June 7, 2021. This trial is evaluating PDS0101 wit
London, UK - 13 May 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) today announced an update on business, as well as financial results for the quarter ended 31 March 2021. PDS Highlights for the Period: · National Cancer Institute to present interim efficacy and safety data of PDS0101 Phase 2 clinical trial in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting on June 7, 2021. This trial is evaluating PDS0101 with two clinical stage immunotherapies from EMD Serono, a first in class bifunctional checkpoint inhibitor Bintrafusp Alfa (M7824) and an antibody conjugated cytokine M9241 (NHS-IL12), in patients with all types of advanced HPV-associated cancers, whose cancer has returned or spread after treatm
PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference
Florham Park, New Jersey (Newsfile Corp. - March 17, 2021) - PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company s immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference on Wednesday, March 24 at 10:05 am ET. In addition, Dr. Bedu-Addo will participate in the Cancer Immunotherapies: Fighting Cancer with the power of the Immune System panel immediately following his presentation at 10:25am ET on Wednesday, March 24.
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.